Tas-102
Chromophobe Renal Cell Carcinoma
M.D. Anderson Cancer CenterunclassifiedPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
11 Active assets in the Chromophobe Renal Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
gw786034 Mayo Clinic | Phase 2 | B |
Bms-907351 Bradley A. McGregor, MD | Phase 2 | B |
Nivolumab Bradley A. McGregor, MD | Phase 2 | CCC |
su011248 M.D. Anderson Cancer Center | Phase 2 | CCC |
Ipilimumab Bradley A. McGregor, MD | Phase 2 | CCC |
View all 16 →
Same molecule, other indications
Tas-102 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →